Biora Therapeutics, Inc. (NASDAQ:BIOR) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET

Company Participants

Chuck Padala – Managing Director, LifeSci Advisors

Adi Mohanty – Chief Executive Officer

Eric d’Esparbes – Chief Financial Officer

Conference Call Participants

Julian Harrison – BTIG

Sahil Kazmi – B. Riley Securities

Operator

Welcome to the Biora Therapeutics First Quarter 2022 Earnings Call. During the presentation, all participants will be in a listen-only mode. Afterwards, we’ll conduct a question-and-answer session. [Operator Instructions] As a reminder, today’s conference is being recorded.

I’ll now turn the call over to Chuck Padala, Managing Director with LifeSci Advisors, Biora Therapeutics Investor Relations firm.

Chuck Padala

Thank you, operator. Good afternoon, and welcome to Biora Therapeutics first quarter 2022 corporate update and financial results conference call. Joining me on the call are Adi Mohanty, Chief Executive Officer; and Eric d’Esparbes, Chief Financial Officer.

Before I turn the call over to Mr. Mohanty, I would like to remind you that today’s call will include forward-looking statements within the meaning of the federal securities laws, including, but not limited to the types of statements identified as forward-looking in our quarterly report on Form 10-Q that we will file later today and our subsequent reports filed with the SEC, which will all be available on our website in the Investors section.

These forward-looking statements represent our views only as of the date of this call and involve substantial risks and uncertainties, including many that are beyond our control. Please note that the actual results could differ materially from those projected in any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements as well as risks related to our business, please see the company’s periodic reports filed with the SEC.

With that, I will now turn the call over to Adi Mohanty, CEO of Biora Therapeutics.

Adi Mohanty

Hello, everyone, and thank you for joining us. First, I’ll review our recent corporate highlights. And then I will recap where we are with each program. We took a big step forward in our transformation as we launched Biora Therapeutics today. The name Biora was chosen to reflect our focus on oral biotherapeutics. Biora’s mission is to reimagine therapeutics and we envision a world where patients have access to life improving therapies without needles.

Biora’s purpose is to develop therapies that improve patient’s health and quality of life by developing innovative smart pills. We’re initially focused on two platforms. One is our novel approach of targeted therapeutics for the treatment of serious GI diseases. We believe we can help patients by delivering a therapeutic formulation directly to the site of disease in the GI tract. Our first program with this platform delivers drug by coding the large intestine with a formulation that’s optimized for topical application. Our targeted approach has been shown to reduce systemic uptake, which has been implicated in toxic or adverse impacts to patients.